Cordex Biologics has entered into an agreement granting FarmaMondo SA distribution rights for its cell therapy product, Zemcelpro® (dorocubicel), in Argentina, Hong Kong and Singapore.

• Therapy Profile: Zemcelpro® is a personalised cryopreserved haematopoietic stem cell transplantation product comprising UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34− cells derived from the same cord blood unit.
• Early Access Strategy: FarmaMondo will support regulatory, market access and specialty distribution activities to facilitate structured early access programmes for eligible patients across the agreed territories.
• Regulatory Status: Zemcelpro® has received conditional marketing authorisation from the European Commission for adults with haematological malignancies requiring allogeneic haematopoietic stem cell transplantation when no suitable donor is available.

This summary is based on a press release issued by ExCellThera via PR Newswire

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.